Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05594056
Other study ID # 2022-600
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 21, 2022
Est. completion date January 31, 2023

Study information

Verified date April 2023
Source Saint Thomas Hospital, Panama
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The neurological alterations associated with preeclampsia depend on cerebral autoregulation, a theory that outlines the mechanisms by which the nervous system controls cerebral perfusion. However, with the loss of autoregulation, increased blood flow, edema and eventually increased intracranial pressure are triggered and may be translated into neurological manifestations such as symptoms of vasospasm, one of the criteria for severity in preeclampsia. Nervous system manifestations frequently found in preeclampsia are headache, blurred vision, scotomas and hyperreflexia. Although uncommon, temporary blindness (lasting a few hours to a week) may also accompany severe preeclampsia and eclampsia. The optic nerve, as part of the central nervous system, is surrounded by cerebrospinal fluid and dura mater, which forms the optic nerve sheath. Due to the connection with the intracranial subarachnoid space, the diameter of the optic nerve sheath is influenced by variations in cerebrospinal fluid pressure. Increased intracranial pressure is transmitted to the subarachnoid space surrounding the optic nerve, causing its expansion. Recent studies suggest that an optic nerve sheath diameter greater than 5 mm correlates 100% with ICP (intracerebral pressure) greater than 20 mm Hg. Due to the simple nature of the test and the limited time required to perform it, it is an ideal non-invasive test to assess changes in mental status, severe headache, and to take the necessary measures aimed at reducing intracranial pressure. The diagnosis of elevated intracranial pressure is challenging and critical, because early recognition and treatment are essential to prevent brain damage or death since preeclampsia with severe data remains one of the most frequent complications in our institution. These values are not taken from the obstetric population, so this study proposes the description of a standard value for the pregnant population. There are few studies that describe a value to help us define cases of this pathology and correlate it with the signs and symptoms of severity in patients with preeclampsia.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 15 Years to 44 Years
Eligibility Inclusion Criteria: - Age between 15-44 years. - Gestational age between 34-40 weeks of gestation. Exclusion Criteria: - Eye disease (Glaucoma, diabetic neuropathy, optic neuritis). - Nervous disorders. - Psychiatric disorders - Diabetes

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Transorbital ultrasound of the optic nerve sheet
Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).

Locations

Country Name City State
Panama Saint Thomas H Panama

Sponsors (1)

Lead Sponsor Collaborator
Saint Thomas Hospital, Panama

Country where clinical trial is conducted

Panama, 

Outcome

Type Measure Description Time frame Safety issue
Primary Optic nerve sheet measurement The diameter of the optic nerve sheath was measured three millimeters behind the eyeball, and one axis perpendicular to the optic nerve. Three measurements were taken in each eye. The resulting six measurements were averaged to give a mean of the optic nerve sheet measurement, to minimize measurement variability. 24 hours
See also
  Status Clinical Trial Phase
Terminated NCT04243278 - Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC) Early Phase 1
Not yet recruiting NCT03318211 - Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Phase 4
Recruiting NCT03761888 - Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Not yet recruiting NCT06373367 - Preeclampsia Educational Program Study (PrEPS) N/A
Not yet recruiting NCT04855513 - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial N/A
Not yet recruiting NCT05232994 - Metformin and Esomeprazole For Preterm Pre-eclampsia Phase 1
Completed NCT04392375 - Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor Phase 4
Recruiting NCT03978767 - Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial Phase 2
Completed NCT04236258 - Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period Phase 4
Completed NCT04756661 - Uterotonics for Severe Preeclampsia N/A
Active, not recruiting NCT04660032 - Nudge to Drive Transitions of Care N/A
Completed NCT04103489 - The Use of Eculizumab in HELLP Syndrome Phase 1
Enrolling by invitation NCT04794855 - Risk Prediction Model of Preeclampsia
Recruiting NCT04311749 - Expanded NIPT for Pregnancy Complications
Active, not recruiting NCT06359015 - Metformin and Esomeprazole in Preterm Pre-eclampsia Phase 4
Recruiting NCT05610774 - Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine N/A
Completed NCT03815110 - Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
Completed NCT03210350 - Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
Completed NCT03451266 - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia Phase 1
Active, not recruiting NCT06360601 - Intravenous Labetalol Versus Hydralazine in Preeclampsia Phase 1/Phase 2